Integration of CGM within Habitual diabetes remission product

将 CGM 整合到习惯性糖尿病缓解产品中

• 批准号: 10041827
• 金额: $ 51.61万
• 依托单位: HABITUAL HEALTH LTD
• 依托单位国家: 英国
• 项目类别: Investment Accelerator
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10041827
• 关键词: Integration; CGM; within; Habitual; diabetes

Type 2 diabetes is on the rise across all of society. Living with type 2 diabetes can result in drastic complications including heart attack, stroke, limb amputation, and blindness. The risk of developing type 2 diabetes increases as a patient ages, and the development of diabetes can significantly impair quality of life, putting a patient at higher risk of dementia and poor quality of life and reducing average lifespan by 5-6 years.At Habitual, we help patients to achieve remission from the type 2 diabetes (where patients are able to return to a normal blood glucose state without medications) through the use of a food product and our companion behaviour change app.By partnering with Innovate UK and Nesta, we will add a new technology, continuous glucose monitoring, to our programmes to allow patients to receive more detailed, highly personalised care, enabling them to have the best chance of sustaining weight loss and remission of type 2 diabetes long into the future.

2型糖尿病在全社会呈上升趋势。患有2型糖尿病会导致严重的并发症，包括心脏病发作，中风，截肢和失明。随着患者年龄的增长，患2型糖尿病的风险会增加，糖尿病的发展会显著损害生活质量，使患者患痴呆症和生活质量差的风险更高，平均寿命缩短5-6年。我们帮助患者从2型糖尿病中获得缓解，通过使用食品和我们的配套行为改变应用程序，患者能够在不使用药物的情况下恢复正常的血糖状态。通过与Innovate UK和Nesta合作，我们将增加一项新技术，持续血糖监测，我们的计划，让患者接受更详细，高度个性化的护理，使他们有最好的机会持续减肥和缓解2型糖尿病的长期未来。